Welcome to the international HTA database

Showing [21996 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Postoperative antimicrobial prophylaxis for thoracic surgery]
2023	Adelaide Health Technology Assessment (AHTA)	Whole genome sequencing for the diagnosis of mitochondrial disease
2023	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Speech-language therapy for laryngeal dysfunction]
2023	Malaysian Health Technology Assessment (MaHTAS)	Bio-electrical impedance analysis for the assessment of sarcopenia in elderly
2023	Adelaide Health Technology Assessment (AHTA)	Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: implantable medical device tracking methods]
2023	Malaysian Health Technology Assessment (MaHTAS)	Nasojejunal tube in upper gastrointestinal conditions
2023	Adelaide Health Technology Assessment (AHTA)	Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
2023	NIHR Health Technology Assessment programme	Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
2023	Malaysian Health Technology Assessment (MaHTAS)	Human skin allograft for burns
2023	Health Information and Quality Authority (HIQA)	Lutetium oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs): evidence synthesis to support a generic justification decision
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)
2023	Malaysian Health Technology Assessment (MaHTAS)	Negative pressure wound therapy
2023	Health Information and Quality Authority (HIQA)	A slot-scanning, biplanar, digital X-ray imaging system for the evaluation and monitoring of orthopaedic conditions: evidence synthesis to support a generic justification decision
2023	Health Information and Quality Authority (HIQA)	Analysis of public consultation surveys to inform the work of the Public Health Reform Expert Advisory Group [protocols and report]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: principles and criteria guiding the use of parent-child trio genomewide sequencing in constitutional genetics - a report to support the work of the RQDM]
2023	Health Information and Quality Authority (HIQA)	Interventions to improve long COVID symptoms: a systematic review
2023	Health Information and Quality Authority (HIQA)	Methods for generic justification of new practices in ionising radiation
2023	Health Information and Quality Authority (HIQA)	Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023	Health Technology Wales (HTW)	Control contact lenses and spectacles for the treatment of myopia in children
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual genes panels of pediatric cancers by NGS of somatic exome and transcriptome - evaluation report of an analysis developed by the RQDM]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in general surgery]
2023	Scottish Health Technologies Group (SHTG)	Priorities for the north imaging alliance
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in hematology/oncology]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: asthma management in children and adults]
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in internal medicine]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: models for coordinating interhospital transfers in critical care]
2023	Scottish Health Technologies Group (SHTG)	Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in neurology]
2023	WorkSafeBC	Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023	Scottish Health Technologies Group (SHTG)	Technology-enabled theatre scheduling systems
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in pediatrics]
2023	WorkSafeBC	Causal association between carpal tunnel release surgery and trigger finger
2023	Scottish Health Technologies Group (SHTG)	Digital prevention programme for people at risk of type 2 diabetes
2023	National Institute for Health and Care Excellence (NICE)	Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Trends in utilisation of ultrasound by older Australians (2010-2019)
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in respirology]
2023	WorkSafeBC	Platelet rich plasma in treating (recurrent) anterior shoulder dislocation
2023	National Institute for Health and Care Excellence (NICE)	Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: virtual care in psychiatry]
2023	WorkSafeBC	Esketamine as treatment for depression and PTSD
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of Intercept and Mirasol - pathogen reduction technologies for the treatment of labile blood products in Quebec]
2023	National Institute for Health and Care Excellence (NICE)	Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023	WorkSafeBC	Botulinum toxin as treatment for neck strains
2023	National Institute for Health and Care Excellence (NICE)	Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023	WorkSafeBC	Migraines and the (Moderna) COVID-19 vaccine
2023	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023	WorkSafeBC	Causal association between COVID-19 infection and irritable larynx syndrome
2023	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023	WorkSafeBC	Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023	National Institute for Health and Care Excellence (NICE)	Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023	WorkSafeBC	Flotation therapy as treatment for concussions
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: Hereditary Cardiovascular diseases NGS Panel - Evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2022	Andalusian Health Technology Assessment Area (AETSA)	Marcapasos sin cable con sincronía aurículo- ventricular para el tratamiento del bloqueo aurículo-ventricular. Actualización.
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Platelet-rich plasma in certain orthopedic conditions]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	ATMPs and gene therapies in development. Horizon scanning – update 2022
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Embolization or sclerotherapy of pelvic veins in pelvic congestion syndrome]
2022	NIHR Health Technology Assessment programme	A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of lung cancer in the Québec context]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: service trajectories and services for at risk or neglected children and their families]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Trastuzumab with pertuzumab in HER2-positive breast cancer]
2022	NIHR Health Technology Assessment programme	SurgiCal Obesity Treatment Study (SCOTS)
2022	Health Information and Quality Authority (HIQA)	High level review of configuration and reform of public health systems in selected countries
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: issues pertaining to the implementation of a clinical decision support system for diagnostic test ordering]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Peer support programs for youth mental health
2022	NIHR Health Technology Assessment programme	Multicentre UK study of the acetylcholinesterase inhibitor donepezil in early dementia associated with Parkinson's disease (MUSTARDD-PD)
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: needs of children at-risk or in situation of neglect and those of their family]
2022	Center for Drug Evaluation (CDE)	The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cryopreservation of eggs and sperm in patients initiating cancer therapy that may affect fertility]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022	NIHR Health Technology Assessment programme	A pragmatic randomised controlled trial and economic evaluation of family therapy vs. treatment as usual for young people seen after second or subsequent episodes of self-harm: the Self-Harm Intervention - Family Therapy (SHIFT) trial
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Promoting mental well-being in children and adolescents]
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Patient bias against healthcare providers
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transient elastography in non-alcoholic fatty liver disease]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stem cell therapy in selected orthopedic conditions]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dapagliflozin for chronic kidney disease
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Biofeedback in adults with urinary and/or fecal incontinence]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Systemic thrombolysis by alteplase for acute ischemic stroke
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Electrosurgical units in surgery]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Systemic thrombolysis and endovascular therapy for large vessel occlusion acute ischemic stroke
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Psychological Treatment for Postpartum Depression]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Swallowable gastric balloon in obesity]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[OncotypeDX in breast cancer]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Vistaseal™ – Intraoperative bleeding]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Coronary intravascular lithotripsy in coronary artery disease]
2022	NIHR Health Technology Assessment programme	Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a randomized controlled trial. PEXIVAS
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions – Part 1: Urinary incontinence]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intensity-modulated radiotherapy for prostate cancer]
2022	Health Information and Quality Authority (HIQA)	Catalogue of institutions undertaking COVID-19 horizon scanning
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Optical coherence tomography angiography in vascular eye diseases]
2022	Institute for Clinical and Economic Review (ICER)	Medications for obesity management: effectiveness and value
2022	Health Information and Quality Authority (HIQA)	Planned public health measures and strategies to limit the impact of COVID-19 surges: an international review
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ultrasound therapy for scar tissue]
2022	Institute for Clinical and Economic Review (ICER)	AMX0035 and oral edaravone for amyotrophic lateral sclerosis
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Advanced lymphoedema: can non-medicinal procedures relieve symptoms?]
2022	NIHR Health Technology Assessment programme	Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2022	Ontario Health	First trimester screening for risk of preeclampsia using a multiple marker algorithm